Jessica Grossman Net Worth

Jessica Grossman biography

Jessica D. Grossman, M.D. is Independent Director of the Company. Prior to her appointment as CEO of Medicines360, Dr. Grossman served as President and Founding CEO of Sense4Baby, Inc., which developed an innovative, wireless maternal fetal heart rate monitoring system for women with high-risk pregnancies. Dr. Grossman was also Founder and President of Gynesonics, Inc., an early-stage medical device company focused on minimally invasive solutions for women's health, which developed the first intrauterine, ultrasound-guided radiofrequency ablation device for fibroid tumors. Dr. Grossman earned a Medical Degree from Sidney Kimmel Medical College at Thomas Jefferson University in Philadelphia and an undergraduate degree with honors from Brandeis University. In addition to her academic and professional accreditations, she has also performed research at the Beth Israel Deaconess Medical Center, part of the Harvard Medical School system.

What's Jessica Grossman's mailing address?

Jessica's mailing address filed with the SEC is 3655 NOBEL DRIVE, SUITE 260, SAN DIEGO, CA, 92122.

Insiders trading at Dare Bioscience Inc

Over the last 7 years, insiders at Dare Bioscience Inc have traded over $0 worth of Dare Bioscience Inc stock and bought 594,545 units worth $703,000 . The most active insiders traders include William H Rastetter, Roger Hawley y Cheryl R Blanchard. On average, Dare Bioscience Inc executives and independent directors trade stock every 152 days with the average trade being worth of $969,110. The most recent stock trade was executed by Roger Hawley on 11 April 2019, trading 454,545 units of DARE stock currently worth $500,000.

What does Dare Bioscience Inc do?

daré bioscience (nasdaq: dare) is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive health. we are driven by a mission to identify, develop and bring to market a diverse portfolio of novel therapies that expand treatment options, improve outcomes and facilitate convenience for women. we are initially focused on the areas of contraception, vaginal health and fertility. our lead product candidate, ovaprene, is a non-hormonal, monthly contraceptive ring that is currently in clinical studies.

Dare Bioscience Inc executives and stock owners

Dare Bioscience Inc executives and other stock owners filed with the SEC include:

• John A. Fair,
  Chief Strategy Officer
• Lisa Walters-Hoffert,
  Chief Financial Officer
• Robin Steele,
  Independent Director
• Gregory Matz,
  Independent Director
• Susan Kelley,
  Independent Director
• Steve Hall,
  Independent Director
• Jessica Grossman,
  Independent Director
• Cheryl Blanchard,
  Independent Director
• John Fair,
  Chief Business Officer
• Jame O'Neill,
  Principal Accounting Officer, Controller, Assistant Treasurer
• Lisa Walters-Hoffert,
  Chief Financial Officer
• Gregg Beloff,
  Principal Financial Officer
• Sabrina Johnson,
  President, Chief Executive Officer, Secretary, Director
• William Rastetter,
  Independent Chairman of the Board
• John Katsilometes,
  Controller
• Mary Jarosz,
  Global Head of Regulatory Affairs
• Dr. David Friend,
  Chief Scientific Officer
• MarDee J. Haring-Layton,
  VP of Accounting & Fin.
• Mark Walters,
  VP of Operations
• Roger Hawley,
  Director
• Mar Dee Haring Layton,
  Chief Accounting Officer
• Sophia Nnenna Ononye Onyia,
  Director